# A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

> **NCT03320629** · PHASE2 · TERMINATED · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 7 (actual)

## Conditions studied

- Refractory or Metastatic Esophageal Squamous Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** apatinib S-1 radiotherapy
- **COMBINATION_PRODUCT:** S-1 radiotherapy

## Key facts

- **NCT ID:** NCT03320629
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-01
- **Primary completion:** 2017-11-01
- **Final completion:** 2018-12-31
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** This study was voluntarily terminated after investigator assessment, with no safety concerns identified related to the trial intervention or procedures. The primary reason for termination was difficulty in patient recruitment.
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03320629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03320629, "A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03320629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*